BR9709700A - Vetor viral célula composição farmacêtica processo de preparação in situ de moléculas de dna circulares replicativas utilização de um vetor viral processo paa a transferência de ácidos nucleícos para uma e molécula de dna circular replicativa - Google Patents

Vetor viral célula composição farmacêtica processo de preparação in situ de moléculas de dna circulares replicativas utilização de um vetor viral processo paa a transferência de ácidos nucleícos para uma e molécula de dna circular replicativa

Info

Publication number
BR9709700A
BR9709700A BR9709700A BR9709700A BR9709700A BR 9709700 A BR9709700 A BR 9709700A BR 9709700 A BR9709700 A BR 9709700A BR 9709700 A BR9709700 A BR 9709700A BR 9709700 A BR9709700 A BR 9709700A
Authority
BR
Brazil
Prior art keywords
viral vector
circular dna
situ
preparing
transfer
Prior art date
Application number
BR9709700A
Other languages
English (en)
Inventor
Michel Perricaudet
Patrice Yeh
Helene Leblois-Prehaud
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of BR9709700A publication Critical patent/BR9709700A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
BR9709700A 1996-06-12 1997-05-23 Vetor viral célula composição farmacêtica processo de preparação in situ de moléculas de dna circulares replicativas utilização de um vetor viral processo paa a transferência de ácidos nucleícos para uma e molécula de dna circular replicativa BR9709700A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9607273A FR2749857B1 (fr) 1996-06-12 1996-06-12 Generation de molecules replicatives in vivo
PCT/FR1997/000914 WO1997047757A1 (fr) 1996-06-12 1997-05-23 Generation de molecules replicatives in vivo

Publications (1)

Publication Number Publication Date
BR9709700A true BR9709700A (pt) 1999-08-10

Family

ID=9492965

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709700A BR9709700A (pt) 1996-06-12 1997-05-23 Vetor viral célula composição farmacêtica processo de preparação in situ de moléculas de dna circulares replicativas utilização de um vetor viral processo paa a transferência de ácidos nucleícos para uma e molécula de dna circular replicativa

Country Status (18)

Country Link
US (1) US6630322B1 (pt)
EP (1) EP0906443B1 (pt)
JP (1) JP2000511779A (pt)
AT (1) ATE301721T1 (pt)
AU (1) AU726442B2 (pt)
BR (1) BR9709700A (pt)
CA (1) CA2257916A1 (pt)
CZ (1) CZ296600B6 (pt)
DE (1) DE69733948T2 (pt)
DK (1) DK0906443T3 (pt)
ES (1) ES2248849T3 (pt)
FR (1) FR2749857B1 (pt)
HU (1) HU224175B1 (pt)
IL (1) IL127430A0 (pt)
NO (1) NO985739L (pt)
SK (1) SK169898A3 (pt)
WO (1) WO1997047757A1 (pt)
ZA (1) ZA975134B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2720756B1 (fr) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
AU2001288839A1 (en) * 2000-09-08 2002-03-22 The General Hospital Corporation Self-rearranging dna vectors
WO2003004088A2 (en) 2001-07-05 2003-01-16 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
US7164056B2 (en) * 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
CN102369288A (zh) * 2008-11-14 2012-03-07 生命技术公司 用于工程化细胞的组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6120764A (en) * 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
EP0632054A1 (en) * 1993-06-28 1995-01-04 European Molecular Biology Laboratory Regulation of site-specific recombination by site-specific recombinase/nuclear receptor fusion proteins
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
AU1695197A (en) * 1996-01-05 1997-08-01 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors

Also Published As

Publication number Publication date
AU726442B2 (en) 2000-11-09
AU3037797A (en) 1998-01-07
FR2749857A1 (fr) 1997-12-19
ATE301721T1 (de) 2005-08-15
HUP9902585A2 (hu) 1999-11-29
FR2749857B1 (fr) 1998-08-14
ZA975134B (en) 1997-12-31
EP0906443A1 (fr) 1999-04-07
NO985739D0 (no) 1998-12-08
DE69733948D1 (de) 2005-09-15
JP2000511779A (ja) 2000-09-12
NO985739L (no) 1998-12-08
EP0906443B1 (fr) 2005-08-10
US6630322B1 (en) 2003-10-07
CA2257916A1 (fr) 1997-12-18
HUP9902585A3 (en) 2001-11-28
DK0906443T3 (da) 2005-12-19
CZ296600B6 (cs) 2006-04-12
HU224175B1 (hu) 2005-06-28
IL127430A0 (en) 1999-10-28
SK169898A3 (en) 1999-07-12
CZ402398A3 (cs) 1999-03-17
WO1997047757A1 (fr) 1997-12-18
ES2248849T3 (es) 2006-03-16
DE69733948T2 (de) 2006-06-08

Similar Documents

Publication Publication Date Title
DE69720473D1 (de) Verfahren zur reinigung von nukleinsäuren
BR9707948A (pt) Processo para obter plantas transplastômicas
BR9607273A (pt) Molécula de dna duplo filamento dna recombinante plasmídio célula recombinante composiçao farmacéutica e processo de preparaçao de uma molécula de dna
IL135776A0 (en) Recombinational cloning using nucleic acids having recombination sites
ATE319854T1 (de) Enzymaktive dna moleküle
DE69636866D1 (en) Reverse "two-hybrid"-systeme
DE69535940D1 (de) Verfahren zur Herstellung von biologischen Produkten in Protein-freiem Kultur
BR9804896B1 (pt) Vetor, polinucleotídeo quimérico, plasmídeo de expressão, e, processo para aumentar a transcrição de um gene de interesse em uma célula hospedeira.
DE68926504D1 (de) Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen
CA2153898A1 (en) Method for generating single-stranded dna molecules
BR9610511A (pt) Molécula de dna de forma circular útil em terapia gênica compreendendo ao menos uma sequência nucléica de interesse processo para sua produção célula recombinante composição farmacêutica utilização de uma molécula de dna e processo de produção de uma proteína recombinante
BR9809433A (pt) Moléculas de dna enzimáticas
ATE304603T1 (de) Induzierendes alphavirengen- expressionssystem
DK0840802T3 (da) Fremgangsmåde til sekvensering gennem oligomerhybridisering
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
WO2003040180A3 (de) Gene von corynebacterium glutamicum, die für genetische stabilitäts-, genexpressions- und faltungsproteine kodieren
ATE301721T1 (de) In vivo herstellung von replicativen molekülen
IL131436A0 (en) Compositions for treatment of disorders involving programmed cell death
DE69839265D1 (de) Modulatoren der expression von morphogenen und deren identifizierungsverfahren
WO2001044198A8 (de) Amphiphile chinolylpolyamine als transfermittel für biologisch aktive makromoleküle
ES2175184T3 (es) Virus que expresan proteinas toxicas y leneas celulares productoras.
BR9810643A (pt) Genes e proteìnas de telomerase de vertebrado, eutilização dos mesmos
FI881294A0 (fi) FSME-viruksen läntisen alatyypin eristettyjä DNA- ja RNA-molekyylejä, näitä sisältäviä vektoreita ja soluviljelmiä sekä menetelmä näiden koodittamien peptidien valmistamiseksi
MX9709596A (es) Adn catal ??tico.
Georgiev Institute of Molecular Biology, Academy of Sciences of

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: AVENTIS PHARMA S.A. (FR)

Free format text: ALTERADO DE: RHONE-POULENC RORER S.A.

B25A Requested transfer of rights approved

Owner name: GENCELL S.A. (FR)

Free format text: TRANSFERIDO DE: AVENTIS PHARMA S.A.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: GENCELL S.A. (FR)

Free format text: A FIM DE ATENDER AO PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO NO 030278/RJ DE 31/05/2004, APRESENTE O DEVIDO DOCUMENTO DE ALTERACAO DE RAZAO SOCIAL.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: GENCELL S.A. (FR)

Free format text: REFERENTE A RPI 1858 COD. (25.6) DE 15/08/2006, POR TER SIDO INDEVIDO.

B25D Requested change of name of applicant approved

Owner name: GENCELL SAS (FR)

Free format text: ALTERADO DE: GENCELL S.A.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements